Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors

Circulation

Volumn 100, Issue 7, 1999, Pages 700-705

  Périard, Daniel ^a   Telenti, Amalio ^a   Sudre, Philippe ^b   Cheseaux, Jean Jacques ^a   Halfon, Patricia ^a   Reymond, Marianne J ^a   Marcovina, Santica M ^c   Glauser, Michel P ^a   Nicod, Pascal ^a   Darioli, Roger ^a   Mooser, Vincent ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Swiss HIV Cohort Study   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

AIDS; Atherosclerosis; Drugs; Hyperlipoproteinemia; Lipoproteins

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LIPOPROTEIN; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; LIPODYSTROPHY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0345151837     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.7.700     Document Type: Article

References (19)

1. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, Rickenbach M, Malinverni R, Vernazza P, Battegay M, Swiss HIV Cohort Study. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ. 1997;315: 1194-1199.
2. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS. 1997;11:938-939.
3. Stocker DN, Meier PJ, Stoller R, Fattinger KE. "Buffalo hump" in HIV-1 infection. Lancet. 1998;352:320-321.
4. Carr A, Samaras K, Burton S, Law M, Freund J. Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
5. Dube MP. Protease inhibitor-associated hyperglycaemia. Lancet. 1997; 350:713-714.
6. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with the use of HIV protease inhibitors. Lancet. 1998;351:1958. Letter.
7. Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M. Vascular complications associated with the use of HIV protease inhibitors. Lancet. 1998;351: 1958-1959. Letter.
8. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with the use of HIV protease inhibitors. Lancet. 1998;351:1959. Letter.
9. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246: 904-910.
10. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52-60.
11. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996;77:1179-1184.
12. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering LDL-cholesterol on cardiovascular risk of lipoprotein(a). JAMA. 1995;274:1771-1774.
13. Ledergerber B, von Overbeck J, Egger M, Lüthy R. The Swiss HIV cohort study: rationale, organization and selected baseline characteristics. Soz Praventivmed. 1994;39:387-394.
14. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41:246-255.
15. Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest. 1996;98:2414-2424.
16. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-proteasse inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet. 1998;351:1881-1883.
17. Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G. Lipoprotein(a) in stored plasma samples and the ravages of time: why epidemiological studies might fail. Arterioscler Thromb Vasc Biol. 1996;16:1568-1572.
18. Henry K, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet. 1998; 352:1031-1032.
19. Dutta SK, Ting CD, Lai LL. Study of prevalence, severity, and etiological factors associated with acute pancreatitis in patients infected with human immunodeficiency virus. Am J Gastroenterol. 1997;92:2044-2048.